---
figid: PMC12065456__peerj-13-19328-g002
figtitle: Pro- and anti-tumorigenic effects of integrins on interaction between endothelial
  cells and particular tumor cells
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC12065456
filename: peerj-13-19328-g002.jpg
figlink: /pmc/articles/PMC12065456/figure/F2/
number: F2
caption: Various integrins communicate with pro- or anti-tumorigenic substances in
  the tumor microenvironment and other receptors on endothelial cells or specific
  tumor cells, thus transmitting pro- or anti-tumorigenic signals through regulating
  FAK, Akt, Erk, MAPK, and NF-κB signaling pathway. Eventually, signals promote or
  impede matrix stiffness, angiogenesis, lymphangiogenesis, and metastasis of tumors.
  EC, endothelial cell; LEC, lymphatic endothelial cell; VN, vitronectin; FG, fibrinogen;
  VEGF, vascular endothelial growth factor; VEGFR2, vascular endothelial growth factor
  receptor 2; Src, Src family kinase; PI3K, phosphatidylinositol 3-phosphokinase;
  Akt, protein kinase B; Rac1, Rac family small GTPase; Cdc42, cell division cycle
  42; Ca2+, calcium ion; MMRN2, multimerin-2; VCAM-1, vascular cell adhesion molecule
  1; CRT, calreticulin; EMILIN-1, recombinant elastin microfibril interface located
  protein 1; Ang-2, angiopoietin 2; NF-κB, nuclear factor kappa B; FAK, focal adhesion
  kinase; MAPK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycin;
  NRP1, n europilin-1; PGE2, prostaglandin E2; COX2, cyclooxygenase-2; MCP1, chemotactic
  protein 1; PIGF, placenta growth factor; bFGF, basic fibroblast growth factor; CXCL1,
  chemokine ligand 1; Erk, extracellular regulated protein kinases; MEK, MAPK kinase;
  uPAR, urokinase-type plasminogen activator receptor; ILK, integrin-linked kinase;
  EGF, epidermal growth factor; L-T4, L-thyroxine; Tetrac, tetraiodothyroacetic acid;
  THBS1, thrombospondin 1; HIF1, hypoxia-induced factor 1; OPN, osteopontin; TRAF2,
  TNF receptor-associated factor 2
papertitle: 'Integrin signaling in tumor biology: mechanisms of intercellular crosstalk
  and emerging targeted therapies'
reftext: Yifan Li, et al. PeerJ. 2025;13(NA).
year: '2025'
doi: 10.7717/peerj.19328
journal_title: PeerJ
journal_nlm_ta: PeerJ
publisher_name: PeerJ, Inc
keywords: Integrins | Tumor | Targeted therapy
automl_pathway: 0.9383571
figid_alias: PMC12065456__F2
figtype: Figure
redirect_from: /figures/PMC12065456__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC12065456__peerj-13-19328-g002.html
  '@type': Dataset
  description: Various integrins communicate with pro- or anti-tumorigenic substances
    in the tumor microenvironment and other receptors on endothelial cells or specific
    tumor cells, thus transmitting pro- or anti-tumorigenic signals through regulating
    FAK, Akt, Erk, MAPK, and NF-κB signaling pathway. Eventually, signals promote
    or impede matrix stiffness, angiogenesis, lymphangiogenesis, and metastasis of
    tumors. EC, endothelial cell; LEC, lymphatic endothelial cell; VN, vitronectin;
    FG, fibrinogen; VEGF, vascular endothelial growth factor; VEGFR2, vascular endothelial
    growth factor receptor 2; Src, Src family kinase; PI3K, phosphatidylinositol 3-phosphokinase;
    Akt, protein kinase B; Rac1, Rac family small GTPase; Cdc42, cell division cycle
    42; Ca2+, calcium ion; MMRN2, multimerin-2; VCAM-1, vascular cell adhesion molecule
    1; CRT, calreticulin; EMILIN-1, recombinant elastin microfibril interface located
    protein 1; Ang-2, angiopoietin 2; NF-κB, nuclear factor kappa B; FAK, focal adhesion
    kinase; MAPK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycin;
    NRP1, n europilin-1; PGE2, prostaglandin E2; COX2, cyclooxygenase-2; MCP1, chemotactic
    protein 1; PIGF, placenta growth factor; bFGF, basic fibroblast growth factor;
    CXCL1, chemokine ligand 1; Erk, extracellular regulated protein kinases; MEK,
    MAPK kinase; uPAR, urokinase-type plasminogen activator receptor; ILK, integrin-linked
    kinase; EGF, epidermal growth factor; L-T4, L-thyroxine; Tetrac, tetraiodothyroacetic
    acid; THBS1, thrombospondin 1; HIF1, hypoxia-induced factor 1; OPN, osteopontin;
    TRAF2, TNF receptor-associated factor 2
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PTK2
  - ACTA1
  - ACTA2
  - ACTB
  - ACTC1
  - ACTG1
  - ACTG2
  - PIGF
  - PGF
  - EPHB2
  - MAPK1
  - MAPK3
  - MTOR
  - AKT1
  - AKT2
  - AKT3
  - TUBE1
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - CCL16
  - ILK
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - KRAS
  - HRAS
  - NRAS
  - PLAUR
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - KDR
  - CDC42
  - COX2
  - PTGS2
  - MTCO2P12
  - RHO
  - RHOD
  - RHOA
  - RHOB
  - RHOC
  - RAC1
  - RNASE1
  - SRC
  - FGR
  - FYN
  - YES1
  - CD93
  - CD36
  - FLT1
  - FLT4
  - NCL
  - DNAJC5
  - VCAM1
  - FGF2
  - EGF
  - SPP1
  - TRAF2
  - TANK
  - HIF1A
  - EPAS1
  - HIF3A
  - ARNT
  - ARNT2
  - BMAL1
  - NFKB1
  - CALCR
  - CALR
  - SLC6A8
  - ANGPT2
  - VPS51
  - MMRN2
  - L-T4
  - Tetrac
  - CRT
  - melanoma
  - cancer
  - Melanoma
  - carcinoma
  - adenocarcinoma
  - Breast cancer
  - Lung adenocarcinoma
  - squamous cell carcinoma
  - Oral squamous cell carcinoma
---
